Medicines Formulary

Reports

Drug name	NICE TAs	Comments
Naloxegol (Moventig®)	TA345 - Naloxegol for treating opioid-induced constipation	For treating opioid-induced chronic constipation - use in line with NICE
Naltrexone tablets	TA115 - Naltrexone for the management of opioid dependence
Natalizumab injection	TA127 - Natalizumab for the treatment of adults with highly active relapsing–remitting multiple sclerosis	For hospital use only
Nilotinib capsules	TA251 - Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia TA241 - Dasatinib, high-dose imatinib and nilotinib for the treatment of imatinib-resistant chronic myeloid leukaemia (CML) (part review of NICE technology appraisal guidance 70), and dasatinib and nilotinib for people with CML for whom treatment with imatinib has failed because of intolerance
Nintedanib	TA379 - Nintedanib for treating idiopathic pulmonary fibrosis TA747 - Nintedanib for treating progressive fibrosing interstitial lung diseases TA864 - Nintedanib for treating idiopathic pulmonary fibrosis when forced vital capacity is above 80% predicted
Nintedanib	TA347 - Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non-small-cell lung cancer
Niraparib	TA528 - Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer TA673 - Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy
Nivolumab (Opdivo®)	TA384 - Nivolumab for treating advanced (unresectable or metastatic) melanoma TA400 - Nivolumab in combination with ipilimumab for treating advanced melanoma TA417 - Nivolumab for previously treated advanced renal cell carcinoma TA462 - Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma TA483 - Nivolumab for previously treated squamous non-small-cell lung cancer TA484 - Nivolumab for previously treated non-squamous non-small-cell lung cancer TA490 - Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy TA558 - Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease TA581 - Nivolumab with ipilimumab for untreated advanced renal cell carcinoma TA655 - Nivolumab for advanced squamous non-small cell lung cancer after chemotherapy TA684 - Nivolumab for adjuvant treatment of completely resected melanoma with lymph node involvement or metastatic disease TA707 - Nivolumab for previously treated unresectable advanced or recurrent oesophageal cancer TA713 - Nivolumab for advanced non-squamous non-small-cell lung cancer after chemotherapy TA716 - Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency TA736 - Nivolumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy TA746 - Nivolumab for adjuvant treatment of resected oesophageal or gastro-oesophageal junction cancer TA817 - Nivolumab for adjuvant treatment of invasive urothelial cancer at high risk of recurrence TA818 - Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma TA857 - Nivolumab with platinum- and fluoropyrimidine-based chemotherapy for untreated HER2-negative advanced gastric, gastro-oesophageal junction or oesophageal adenocarcinoma TA865 - Nivolumab with fluoropyrimidine- and platinum-based chemotherapy for untreated unresectable advanced, recurrent, or metastatic oesophageal squamous cell carcinoma TA876 - Nivolumab with chemotherapy for neoadjuvant treatment of resectable non-small-cell lung cancer
Nusinersen	TA588 - Nusinersen for treating spinal muscular atrophy
Obeticholic acid (Ocaliva®)	TA443 - Obeticholic acid for treating primary biliary cholangitis	Off label use. Consultant initiation only (gastro use). Hospital only - in line with NICE TA443.

First page
Previous page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
Next page
Last page

Drug status key

Formulary drugs are allocated a traffic light status. This provides guidance on where clinical and prescribing responsibilities lie in regard to the initiation and maintenance of prescribing.

Grey

Positive NICE TA and/or awaiting local clarification on place in therapy. Please contact your medicines optimisation team for more information.

Red

Initiation and maintenance of prescribing by specialists only.

Amber

Initiation and maintenance of prescribing by specialists and transfer to primary care prescribing when appropriate, or in primary care following a specialists recommendation. Prior to initiation some medicines may require committee agreement or a framework to support safe transfer and maintenance.

Green

Initiation and maintenance of prescribing by specialists, GPs and other qualified clinicians.

Blue

Under review at University Hospitals Birmingham NHS Foundation Trust.